United Therapeutics Co. (NASDAQ:UTHR) Receives $388.25 Consensus PT from Analysts

Shares of United Therapeutics Co. (NASDAQ:UTHR) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $388.25.

Several research firms recently issued reports on UTHR. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th.

United Therapeutics Trading Up 5.1 %

UTHR stock opened at $322.94 on Friday. The company has a market capitalization of $14.50 billion, a PE ratio of 14.18, a P/E/G ratio of 0.97 and a beta of 0.64. United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82. The business’s fifty day moving average price is $349.12 and its 200 day moving average price is $358.27.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the business earned $4.36 EPS. Research analysts predict that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, Director Louis W. Sullivan sold 26,209 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares of the company’s stock, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Nilda Mesa sold 255 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,464 shares of company stock worth $42,396,244 over the last quarter. 11.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC boosted its stake in shares of United Therapeutics by 15.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,643 shares of the biotechnology company’s stock worth $1,991,000 after acquiring an additional 769 shares in the last quarter. NorthCrest Asset Manangement LLC boosted its stake in shares of United Therapeutics by 1.5% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 5,598 shares of the biotechnology company’s stock worth $1,975,000 after acquiring an additional 84 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ bought a new stake in shares of United Therapeutics during the 4th quarter worth $4,778,000. Siemens Fonds Invest GmbH bought a new stake in shares of United Therapeutics during the 4th quarter worth $162,000. Finally, Park Square Financial Group LLC bought a new stake in shares of United Therapeutics during the 4th quarter worth $217,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.